Fate Therapeutics News and Activities
Presence
Fate Therapeutics develops cell-based cancer and immune disorder treatments. Its main products and services include cell therapy programs and research partnerships for hospitals, clinics, and pharmaceutical companies.
Fate Therapeutics products and services overview:
- Cell therapies
- Cancer treatments
- Immune therapies
- Research services
- Drug development
Revenue: ~$58 million
Employees: 220
Headquarters: San Diego, United States (USA)
Fate Therapeutics is one of the...
Fate Therapeutics is a company listed under the stock ticker FATE (US).
Executives
View the org chart displaying its 30 main executives
Most searched biographies at Fate Therapeutics
- Bob Valamehr, Chief Executive Officer and President
- Shefali Agarwal, Director
- Michael Lee, Board Member
Popular executive movements at Fate Therapeutics
- Kamal Adawi will join the company as Chief Financial Officer on Oct. 20, 2025 (posted on October 14 2025).
Create your alert
to follow the executive moves at Fate Therapeutics.
Biotechnology
Fate Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Fate Therapeutics
- Press Releases | Fate Therapeutics, Inc.
- Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress | Fate Therapeutics, Inc.
- Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results | Fate Therapeutics, Inc.
- Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies | Fate Therapeutics, Inc.
- Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer | Fate Therapeutics, Inc.
- Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference | Fate Therapeutics, Inc.
- Fate Therapeutics to Present at Upcoming May Investor Conferences | Fate Therapeutics, Inc.
- Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress | Fate Therapeutics, Inc.
- Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support | Fate Therapeutics, Inc.
- Fate Therapeutics to Present at Upcoming Investor Conferences | Fate Therapeutics, Inc.
- View more press releases Close
Social media about Fate Therapeutics
- Fate Therapeutics on Wikipedia, Google News & Yahoo Finance
- Fate Therapeutics on LinkedIn, X (Twitter) & YouTube
